Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 9/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | SMO | Q99835 | 1/20 | 0.53 |
| ▸ | SCD | O00767 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25235892 | 0.81 | MAPT (0.55) | TP53MAPTSMN1; SMN2GAATSHR | |
| SCHEMBL30445763 | 0.81 | SMN1; SMN2 (0.55) | TP53MAPTSMN1; SMN2LMNAGAA | |
| SCHEMBL25229602 | 0.81 | SMN1; SMN2 (0.55) | TP53MAPTSMN1; SMN2LMNAGAA | |
| SCHEMBL25245419 | 0.81 | ABCB1 (0.58) | MAPTSMN1; SMN2POLBMAPK14SMO | |
| SCHEMBL30445445 | 0.81 | ABCB1 (0.58) | MAPTSMN1; SMN2POLBMAPK14SMO | |
| SCHEMBL30445554 | 0.79 | MAPT (0.78) | TP53MAPTSMN1; SMN2LMNAPOLB | |
| SCHEMBL25209983 | 0.79 | MAPT (0.78) | TP53MAPTSMN1; SMN2LMNAPOLB | |
| SCHEMBL30446589 | 0.79 | MAPT (0.68) | TP53MAPTSMN1; SMN2LMNARXFP1 | |
| SCHEMBL25208976 | 0.79 | MAPT (0.68) | TP53MAPTSMN1; SMN2LMNARXFP1 | |
| SCHEMBL25214891 | 0.78 | MAPT (0.55) | TP53MAPTSMN1; SMN2GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4153172-B1 | COMPOUNDS FOR USE IN THE REACTIVATION OF HIV IN LATENT HIV-INFECTED CELLS | CENTRE NAT RECH SCIENT (FR) | 2024-11-27 | — | — | EP | disclosed |
| US-20230172913-A1 | COMPOUNDS FOR USE IN THE REACTIVATION OF HIV IN LATENT HIV-INFECTED CELLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-06-08 | — | — | US | disclosed |
| US-20230172913-A1 | COMPOUNDS FOR USE IN THE REACTIVATION OF HIV IN LATENT HIV-INFECTED CELLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-06-08 | — | — | US | disclosed |
| US-20230172913-A1 | COMPOUNDS FOR USE IN THE REACTIVATION OF HIV IN LATENT HIV-INFECTED CELLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172913-A1 | COMPOUNDS FOR USE IN THE REACTIVATION OF HIV IN LATENT HIV-INFECTED CELLS | TARBP1, NFATC1, TARDBP | TP53 821/4885MAPT 781/4885SMN1; SMN2 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.